As a leading pharmaceutical company at the forefront of medical innovation, Biovico is proud to announce our strategic initiative to develop groundbreaking solutions centered around hyaluronic acid.
With a commitment to advancing patient care and enhancing the quality of life, our dedicated team is poised to revolutionize the field of joint health through the therapeutic potential of hyaluronic acid.
Understanding the significance of hyaluronic acid
Joints play a key role in functioning of musculoskeletal system, thus limitations in their function resulting from degeneration that lead to pain and discomfort significantly affect patients quality of life. Due to these pathologies affecting joint are a challenge constantly addressed by teams of researchers, clinicians and engineers not only seeking for new forms of therapy but also disease prevention.
Hyaluronic acid (HA), as the main component of the synovial fluid in the joints, plays a significant role in lubricating and cushioning of the joint tissues, allowing for the frictionless movement, thus being essential factor in patients mobility. HA is present not only in synovial fluid, being responsible for its high viscosity, but it is also essential component of the articular cartilage structure, where with aggrecans and collagens provides refined matrix network giving tissue is mechanical resistance.
Being fully aware of a fundamental role of HA and its importance in joint mobility, Biovico aims to use its unique properties in order to create therapies that can be applied to various joint-related pathologies.
Key Focus Areas for Hyaluronic Acid Solutions:
1. Intra-Articular Injections
Biovico's research and development efforts are focused on refining intra-articular injections of hyaluronic acid. For the past years Biovico has developed and introduced a whole range of hyaluronic acid injectable products with perfectly matched properties. Years of experience, including numerous laboratory experiments and clinical studies, resulted in a wealth of knowledge on importance of HA physicochemical properties in its mechanism of action during potential therapeutic applications. Biovico's injectable products are characterized with optimally high molecular weight, individually adjusted concentration of sodium hyaluronate what finally results in appropriate viscosity of each gel dedicated for specific application. Our HA-based treatments have shown a great clinical promise in providing symptomatic relief for conditions such as osteoarthritis and injuries.
Biovico's research and development efforts are focused on refining intra-articular injections of hyaluronic acid. For the past years Biovico has developed and introduced a whole range of hyaluronic acid injectable products with perfectly matched properties. Years of experience, including numerous laboratory experiments and clinical studies, resulted in a wealth of knowledge on importance of HA physicochemical properties in its mechanism of action during potential therapeutic applications. Biovico's injectable products are characterized with optimally high molecular weight, individually adjusted concentration of sodium hyaluronate what finally results in appropriate viscosity of each gel dedicated for specific application. Our HA-based treatments have shown a great clinical promise in providing symptomatic relief for conditions such as osteoarthritis and injuries.
Biovico continues to strive for excellence, continuing the development of more effective and innovative products that will bring relief to patients suffering from even more advanced joint pathologies.
2. Beyond pure HA in the synovial joint: The triad of perfect joint lubrication
Following the global direction in the search for the ideal synovial fluid substitute that aims to enhance the therapeutic potential of therapies based on intra-articular injections, our research and development center developed Biovico’s own innovative approach for viscosupplementation. Notably, literature data show that hyaluronic acid is able to provide ideal lubrication parameters in the joint only when it forms a direct link with phospholipids in a form of liposomes. Furthermore, the latest scientific research in the field of surface mechanics indicates that only the combination of hyaluronic acid and liposomes interacts molecularly with proteins on the surface of articular cartilage- lubricin, creating surfaces with virtually negligible friction. Based on that knowledge, Biovico created an intra-articular (I-A) injectable product that mimics and makes applicable the use of SYNERGY between HIALURONIC ACID linked with PHOSPHOLIPIDS in form of liposomes that further interacts with LUBRICIN in order to provide lowered friction. Biovico created the theory of ideal joint lubrication TRIAD which is used in Lipotris™- a liposomal intra-articular gel.
Consequently, further rigorously designed clinical trial of Lipotris™ delivered solid data for clinical functionality of the therapy based on three injections of liposomal intra-articular gel into OA affected joints. Obtained clinical data served as a cornerstone for the successful introduction of a Lipotris™ to the market, and at the same time solidified the clinical significance of the ideal lubrication with HA and liposomes in synovial joint functioning.
3. Customized Treatment Plans:
Biovico recognizes the importance of personalized medicine. Our approach involves tailoring hyaluronic acid-based treatment plans to the unique needs of each patient. By considering factors such as the severity of the condition and individual patient characteristics, we aim to optimize treatment outcomes. With such a wide range of IA injections we are able to provide a tailored approach depending on individual patient characteristics, the severity of OA, and the specific goals of treatment with the following route:
I. Patient assessment
II. Determination of the severity of osteoarthritis
III. Consideration of treatment goals
IV. Frequency and timing of treatment accepted by the patient
V. Selecting the appropriate intra-articular solution
VI. Possible combination therapies with other agents like PRP or DKK-1 rich blood derived product
VII. Monitoring and treatment follow-up